Proactive - Interviews for investors
Solvonis CEO: Phase III is where the real value gets created
Anthony Tennyson, CEO of Solvonis, discusses the company's strategic rebrand and acquisition of Awakn Life Sciences. He explains the decision to advance lead program SVN-001 through Phase III trials, highlighting the potential for increased shareholder value.